Hormonal therapy in patients with breast cancer is based on estrogen blockade of tumor cell growth. In postmenopausal patients tamoxifen still represents the hormonal agent of first choice and has shown to induce remission in patients with metastatic disease, to reduce recurrence, and to improve overall survival in the adjuvant setting. However, side effects such as slightly increased incidence of endometrial cancer have stimulated the search for other substances. Substantial progress in the development of anti-estrogens have yielded in substances with different antagonistic/agonistic profils (Tore-mifen, Raloxifen, Droloxifen, Idoxifen, ICI 182,780), which are currently tested in phase II and III studies. In the group of the aromatase inhibitors, which are mostly used in second-line protocols, new compounds are on the market (Formestan, Anastrazol, Letrozol, Vorozol, Fadrozol) which circumvent the main problem of inhibition of the glucocorticoid synthesis of the first-generation drugs (glutethimide) by better specificity. These already are widely used in patients with tamoxifen-resistant tumors. Whether these substances can also improve the outcome in first-line therapy is currently under clinical evaluation. An additional therapeutic intervention is the pharmacological castration (Goserelin), which orginates from the optimistic result of the surgical castration earlier days. This concept is used in premenopausal patients and currently studied alternatively and in addition to tamoxifen. In general there is hope to improve efficacy and to reduce side effects of endocrine treatment with these new compounds in the near future.

This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.